A woman's gynecologic health includes a range of reproductive and female-specific needs that change over time, depending upon her age, exposure to external factors, and family planning interests. Roche is making a significant investment in the areas of healthcare that are meaningful to women when it comes to maintaining wellness, supporting reproduction, fertility and pregnancy, as well as disease prevention through certain female screening and monitoring assays. Our advanced diagnostic solutions use innovative technology to provide answers that help guide clinical care decisions for a patient, individualizing her care based on information from the right test, at the right time. In the Gynecology area, this is especially important during pregnancy, all the way from conception planning to delivery.
Because 1 in every 6 couples globally has trouble conceiving,1 we created a non-invasive blood test that reveals approximately how many eggs remain in a woman’s ovaries. Our anti-Müllerian hormone (AMH) fertility test empowers a woman to make decisions based on definitive information.
For pregnant women, we have diagnostics solutions that can provide peace of mind and prevent unnecessary hospitalizations. For example, the sFlt-1/PlGF ratio of biomarkers is derived from a simple blood test. This ratio can help rule out symptomatic pregnant women who will not develop preeclampsia in the next one week with more than 99% certainty.2 We also have a Non-invasive Prenatal Test (NIPT) that uses cell-free DNA from blood to screen for common chromosomal conditions in the baby, such as, trisomy 21, 18, and 13.
The discovery that human papillomavirus (HPV) causes 99% of all cervical cancers3 revolutionized our approach to this preventable but deadly disease. Our HPV screening test quickly identifies which women have been infected with the high-risk forms of the virus, giving their healthcare providers clear information to guide patient management decisions. As is the case with HPV, many women with other sexually transmitted infections (STIs) can be asymptomatic for a long time. Screening catches STIs before they can cause serious complications, such as infertility from chlamydia or miscarriage from syphilis.
